Filtered By:
Source: The American Journal of Cardiology
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 75 results found since Jan 2013.
Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction HORIZONS-AMI Substudy)
The present study sought to determine the extent to which adverse angiographic events encountered during percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI) are associated with adverse clinical outcomes. Patients with STEMI represent a cohort at particularly high risk of intraprocedural thrombotic events (IPTEs). The overall frequency and implications of IPTEs occurring in patients with STEMI have not been systematically quantified in previous studies. A total of 3,163 patients undergoing primary percutaneous coronary intervention with stent implantation for STEMI in the Harmonizing Ou...
Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Ajay J. Kirtane, Prabhdeep Sandhu, Roxana Mehran, Margaret McEntegart, Ecaterina Cristea, Sorin J. Brener, Ke Xu, Martin Fahy, Philippe Généreux, Jeffrey D. Wessler, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research
Comparison of Statin Alone Versus Bezafibrate and Statin Combination in Patients With Diabetes Mellitus and Acute Coronary Syndrome
In conclusion, a significantly lower risk for 30-day MACEs was observed in statin-treated patients with DM who also received bezafibrate after ACS. Signals regarding improvement of 30-day rehospitalization and 1-year mortality rates emerged as well.
Source: The American Journal of Cardiology - October 24, 2013 Category: Cardiology Authors: Robert Klempfner, Ilan Goldenberg, Enrique Z. Fisman, Shlomi Matetzky, Uri Amit, Joseph Shemesh, Alexander Tenenbaum Tags: Coronary Artery Disease Source Type: research
Contemporary Analysis of Incidence and Outcomes of Stent Thrombosis Presenting as ST Elevation Myocardial Infarction in a Primary Percutaneous Coronary Intervention Cohort
There are limited data about the effectiveness of primary percutaneous coronary intervention (PPCI) for stent thrombosis treatment. We aimed to evaluate the prevalence and outcomes of PPCI in patients with ST elevation acute myocardial infarction (STEMI) due to stent thrombosis, and comparing the outcomes with patients treated for de novo coronary thrombosis. This was an observational cohort study of 2,935 patients who underwent PPCI from 2003 to 2011 with follow-up for a median of 3.0 years (interquartile range 1.2 to 4.6). The primary end point was the first major adverse cardiac event (MACE) defined as death, nonfatal ...
Source: The American Journal of Cardiology - September 9, 2013 Category: Cardiology Authors: Daniel A. Jones, Sean Gallagher, Krishnaraj S. Rathod, Mohammed Akhtar, Charles J. Knight, Martin T. Rothman, Akhil Kapur, Anthony Mathur, Ajay K. Jain, Adam D. Timmis, Elliot J. Smith, Andrew Wragg Tags: Coronary Artery Disease Source Type: research
Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery
In conclusion, in patients with STEMI who underwent primary PCI of LAD, the use of bivalirudin was associated with a reduction in mortality and bleeding rates at 3 years. PES reduced revascularization rates in this population but did not have a significant impact on mortality.
Source: The American Journal of Cardiology - June 10, 2013 Category: Cardiology Authors: Jochen Wöhrle, Bruce Brodie, Bernhard Witzenbichler, Dariusz Dudek, Ran Kornowski, Chris Metzger, Cindy Grines, Thomas C. McAndrew, Helen Parise, Ziad Sergie, Roxana Mehran, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research
Efficacy of the CHADS2 Scoring System to Assess Left Atrial Thrombogenic Milieu Risk Before Cardioversion of Non-Valvular Atrial Fibrillation
In this study, data from 2,369 consecutive patients in whom transesophageal echocardiography was performed for screening before direct-current cardioversion from 1999 to 2008 were analyzed. Left atrial (LA) or LA appendage (LAA) thrombogenic milieu (spontaneous echo contrast, sludge, and thrombus) was investigated. The results were correlated with CHADS2 score findings. The mean age was 66 ± 13 years, and the ratio of men to women was 2.2:1. CHADS2 scores of 0, 1, 2, 3, 4, 5 and 6 were present in 11%, 25%, 30%, 22%, 8%, 3%, and 1% of the studies, respectively. The prevalence of LA or LAA sludge or thrombus increased with ...
Source: The American Journal of Cardiology - May 31, 2013 Category: Cardiology Authors: Hirad Yarmohammadi, Tristan Klosterman, Gaganpreet Grewal, M. Chadi Alraies, Brandon C. Varr, Bruce Lindsay, Andrew O. Zurick, Kevin Shrestha, W.H. Wilson Tang, Mandeep Bhargava, Allan L. Klein Tags: Arrhythmias and Conduction Disturbances Source Type: research
Usefulness of Local Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (the Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention DISSOLUTION Randomized Trial)
In conclusion, local, intrathrombus delivery of thrombolytics before manual thrombectomy improved the postprocedural coronary flow and myocardial perfusion and the 6-month clinical outcomes.
Source: The American Journal of Cardiology - May 28, 2013 Category: Cardiology Authors: Cesare Greco, Francesco Pelliccia, Gaetano Tanzilli, Maria Denitza Tinti, Paola Salenzi, Cristina Cicerchia, Michele Schiariti, Ferdinando Franzoni, Giuseppe Speziale, Pietro Gallo, Carlo Gaudio Tags: Coronary Artery Disease Source Type: research
Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2–TIMI 51)
In conclusion, the 2 doses of rivaroxaban reduced cardiovascular events in patients with recent acute coronary syndromes treated with antiplatelet therapies; however, the 2.5-mg dose was associated with lower mortality and fewer bleeding complications than the 5-mg dose. Thus, the addition of rivaroxaban 2.5 mg twice daily offers a more favorable balance of efficacy and safety in patients with recent acute coronary syndromes.
Source: The American Journal of Cardiology - May 28, 2013 Category: Cardiology Authors: Jessica L. Mega, Eugene Braunwald, Stephen D. Wiviott, Sabina A. Murphy, Alexei Plotnikov, Nina Gotcheva, Mikhail Ruda, C. Michael Gibson Tags: Coronary Artery Disease Source Type: research
Thrombocytopenia in Patients With Atrial Fibrillation on Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
In conclusion, mild to moderate baseline thrombocytopenia does not seem to have a clinically significant effect on bleeding or thrombotic or thromboembolic complications after PCI in these frail patients receiving multiple antithrombotic drugs.
Source: The American Journal of Cardiology - May 13, 2013 Category: Cardiology Authors: Tuomas Kiviniemi, Pasi Karjalainen, Andrea Rubboli, Axel Schlitt, Petri Tuomainen, Matti Niemelä, Mika Laine, Fausto Biancari, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Coronary Artery Disease Source Type: research
Dabigatran and Acute Coronary Syndromes
There has been considerable interest in the utility of newer oral anticoagulants for the secondary prevention of myocardial infarction (MI) and acute coronary syndromes (ACS). The direct thrombin inhibitor dabigatran has been approved for stroke prevention in patients with atrial fibrillation. However, as Verheugt discussed, when combined with dual antiplatelet therapy for secondary prevention in patients with ACS, no difference was found between the placebo and dabigatran groups for the composite end point of cardiovascular death, nonfatal MI, or stroke. However, it should also be noted that recent reports have actually ...
Source: The American Journal of Cardiology - May 1, 2013 Category: Cardiology Authors: John R. Kapoor Tags: Readers' Comments Source Type: research
Between a Rock and a Hard Place: Weighing Thrombotic Risk Against Bleeding Complications
The prospect of a further reduction of thrombotic end points (stent thrombosis, acute coronary syndromes, ischemic stroke) may seem appealing and encouraging to clinicians, interventional cardiologists in particular. Be that as it may, are we willing to accept a further reduction in thrombotic events at the trade-off of increasing hemorrhagic risk?
Source: The American Journal of Cardiology - April 25, 2013 Category: Cardiology Authors: Bartosz Hudzik, Lech Polonski Tags: Readers' Comments Source Type: research
Safety of Continuous Anticoagulation With Dabigatran During Implantation of Cardiac Rhythm Devices
In conclusion, although no thromboembolic or major bleeding events were observed, additional studies are required to define the optimal antithrombotic management in the perioperative period.
Source: The American Journal of Cardiology - January 28, 2013 Category: Cardiology Authors: Christopher P. Rowley, Michael L. Bernard, William W. Brabham, Peter C. Netzler, Darren S. Sidney, Frank Cuoco, J. Lacy Sturdivant, Robert B. Leman, J. Marcus Wharton, Michael R. Gold Tags: Arrhythmias and Conduction Disturbances Source Type: research
Renal Impairment in a “Real-Life” Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding)
In conclusion, the presence of impaired renal function was closely related to thrombotic/vascular events, bleeding, and mortality in anticoagulated patients with AF. During follow-up, 1/5 of the patients had significant impairment in renal function. Importantly, normal or mild renal dysfunction at baseline did not exclude the subsequent development of severe renal dysfunction during the follow-up period.
Source: The American Journal of Cardiology - January 21, 2013 Category: Cardiology Authors: Vanessa Roldán, Francisco Marín, Hermógenes Fernández, Sergio Manzano-Fernández, Pilar Gallego, Mariano Valdés, Vicente Vicente, Gregory Y.H. Lip Tags: Arrhythmias and Conduction Disturbances Source Type: research
Contribution of Three-Dimensional Transesophageal Echocardiography to Diagnosis and Management of Thrombosis of a St. Jude Mechanical Prosthesis in the Aortic Valve Position
Prosthetic valve thrombosis (PVT) is a serious complication after cardiac valve replacement and usually requires urgent management with either thrombolysis or surgery. A 38-year-old woman with history of ischemic stroke and multiple valvular surgeries including aortic St. Jude mechanical valve replacement (St. Jude Medical, St. Paul, Minnesota) presented with new-onset dyspnea on exertion. Transthoracic echocardiography and 2-dimensional transesophageal echocardiography (TEE) suggested an abnormally high gradient across the aortic valve () but could not determine the cause of the stenosis (, ). Three-dimensional (3D) TEE...
Source: The American Journal of Cardiology - January 4, 2013 Category: Cardiology Authors: Kan Liu Tags: Readers' Comments Source Type: research
Comparison of Procedural Success and Long-Term Outcomes of Stent Thrombosis in Coronary Bypass Grafts Versus Native Coronary Arteries
Percutaneous coronary intervention within bypass grafts accounts for a significant percentage of total interventions. Bypass graft interventions are associated with an increased risk for stent thrombosis (ST), a condition that leads to significant morbidity and mortality. Despite this, the procedural characteristics and long-term outcomes of patients with bypass-graft ST have not been reported. The aim of the present study was to evaluate the procedural success and long-term outcomes of patients presenting with ST of coronary bypass grafts. Clinical and procedural characteristics of 205 ST cases at 5 academic hospitals wer...
Source: The American Journal of Cardiology - December 20, 2012 Category: Cardiology Authors: Stephen W. Waldo, Ehrin J. Armstrong, Khung Keong Yeo, Ehtisham Mahmud, Mitul Patel, Ryan Reeves, John S. MacGregor, Reginald I. Low, Jason H. Rogers, Kendrick A. Shunk Tags: Coronary Artery Disease Source Type: research
